KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2-breast cancer

被引：0
|
作者：
Cardoso, F. [1 ]
Bardia, A. [2 ]
Andre, F. [3 ]
Cescon, D. W. [4 ]
McArthur, H. [5 ]
Telli, M. [6 ]
Loi, S. [7 ]
Cortes, J. [8 ]
Schmid, P. [9 ]
Harbeck, N. [10 ]
Denkert, C. [11 ]
Jackisch, C. [12 ]
Jia, L. [13 ]
Hirshfield, K. [14 ]
Karantza, V. [15 ]
机构：
[1] Champalimaud Fdn Canc Ctr, Breast Unit, Lisbon, Portugal
[2] Harvard Med Sch, Massachusetts Gen Hosp, Med Oncol, Boston, MA 02115 USA
[3] Gustave Roussy Canc Campus, Med Oncol Dept, Breast Canc Unit, Villejuif, France
[4] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
[5] Cedars Sinai Med Ctr, Breast Oncol, Los Angeles, CA 90048 USA
[6] Stanford Univ, Sch Med, Med Med Oncol, Stanford, CA USA
[7] Peter MacCallum Canc Ctr, Div Res, Translat Breast Canc Genom Lab, Melbourne, Vic, Australia
[8] Ramon & Cajal Univ Hosp, Breast Canc Program, Madrid, Spain
[9] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
[10] Ludwig Maximilians Univ Grosshadern, Breast Ctr, Munich, Germany
[11] Uniklinikum Giessen & Marburg, Inst Pathol, Marburg, Germany
[12] Klinikum Offenbach GmbH, Obstet & Gynecol, Offenbach, Germany
[13] Merck & Co Inc, Biostat, Kenilworth, NJ USA
[14] Merck & Co Inc, Oncol Late Stage Dev, Kenilworth, NJ USA
[15] Merck & Co Inc, Clin Res Oncol, Kenilworth, NJ USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
24TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [1] KEYNOTE-756: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab or Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for High-Risk, Early-Stage, ER+/HER2-Breast Cancer
    Hirshfield, Kim
    Cardoso, Fatima
    Bardia, Aditya
    Andre, Fabrice
    Cescon, David
    McArthur, Heather
    Telli, Melinda
    Loi, Sherene
    Cortes, Javier
    Schmid, Peter
    Harbeck, Nadia
    Denkert, Carsten
    Jackisch, Christian
    Jia, Liyi
    Karantza, Vassiliki
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 2) : S288 - S288
  • [2] KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2-breast cancer
    Cardoso, F.
    Bardia, A.
    Andre, F.
    Cescon, D. W.
    McArthur, H.
    Telli, M.
    Loi, S.
    Cortes, J.
    Schmid, P.
    Harbeck, N.
    Denkert, C.
    Jackisch, C.
    Jia, L.
    Tryfonidis, K.
    Karantza, V.
    CANCER RESEARCH, 2019, 79 (04)
  • [3] Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/ HER2-breast cancer: KEYNOTE-756
    Cardoso, Fatima
    O'Shaughnessy, Joyce
    McArthur, Heather
    Schmid, Peter
    Cortes, Javier
    Harbeck, Nadia
    Telli, Melinda
    Cescon, David
    Fasching, Peter A.
    Shao, Zhimin
    Loirat, Delphine
    Park, Yeon Hee
    Fernandez, Manuel Gonzalez
    Rubovszky, Gabor
    Im, Seock-Ah
    Hui, Rina
    Takano, Toshimi
    Andre, Fabrice
    Yasojima, Hiroyuki
    Liu, Zhenzhen
    Ding, Yu
    Jia, Liyi
    Karantza, Vassiliki
    Tryfonidis, Konstantinos
    Bardia, Aditya
    CANCER RESEARCH, 2024, 84 (09)
  • [4] Neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for earlystage high-risk ER+/HER2-breast cancer: Results from the phase 3 KEYNOTE-756 study
    Cardoso, F.
    O'Shaughnessy, J.
    McArthur, H.
    Schmid, P.
    Cortes, J.
    Harbeck, N.
    Telli, M. L.
    Cescon, D. W.
    Fasching, P.
    Shao, Z.
    Loirat, D.
    Park, Y. H.
    Gonzalez Fernandez, M.
    Rubovszky, G.
    Im, S. A.
    Hui, R.
    Takano, T.
    Andre, F.
    Yasojima, H.
    Liu, Z.
    Ding, Y.
    Jia, L.
    Karantza, V.
    Tryfonidis, K.
    Bardia, A.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 10 - 11
  • [5] Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+HER2-breast cancer :KEYNOTE-756
    Cardoso, Fatima
    O'Shaughnessy, Joyce
    McArthur, Heather
    Schmid, Peter
    Cortes, Javier
    Harheck, Nadia
    Telli, Melinda L.
    Cescon, David W.
    Fasching, Peter A.
    Shao, Zhimin
    Loirat, Delphine
    Park, Yeon Hee
    Gonzalez Fernandez, Manuel
    Rubovszky, Gabor
    Im, Seock-Ah
    Hui, Rina
    Takano, Toshimi
    Andre, Fabrice
    Yasojima, Hiroyuki
    Liu, Zhenzhen
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S4 - S5
  • [6] KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy (chemo), followed by adjuvant pembro or pbo plus endocrine therapy (ET) for early-stage high-risk ER+/HER2e breast cancer
    Cardoso, F.
    McArthur, H. L.
    Schmid, P.
    Cortes, J.
    Harbeck, N.
    Telli, M. L.
    Cescon, D. W.
    O'Shaughnessy, J.
    Fasching, P.
    Shao, Z.
    Loirat, D.
    Park, Y. H.
    Fernandez, M. E. Gonzalez
    Liu, Z.
    Yasojima, H.
    Ding, Y.
    Jia, L.
    Karantza, V. V.
    Tryfonidis, K. E.
    Bardia, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1260 - S1261
  • [7] KEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo plus neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor-positive human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer (BC)
    Cardoso, F.
    Jia, L.
    Hirshfield, K.
    Karantza, V.
    ANNALS OF ONCOLOGY, 2019, 30 : 38 - 38
  • [8] KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
    Cardoso, Fatima
    Bardia, Aditya
    Andre, Fabrice
    Cescon, David W.
    McArthur, Heather L.
    Telli, Melinda L.
    Loi, Sherene
    Cortes, Javier
    Schmid, Peter
    Harbeck, Nadia
    Denkert, Carsten
    Jackisch, Christian
    Jia, Liyi
    Hirshfield, Kim M.
    Karantza, Vassiliki
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial
    Cardoso, Fatima
    O'Shaughnessy, Joyce
    Liu, Zhenzhen
    Mcarthur, Heather
    Schmid, Peter
    Cortes, Javier
    Harbeck, Nadia
    Telli, Melinda L.
    Cescon, David W.
    Fasching, Peter A.
    Shao, Zhimin
    Loirat, Delphine
    Park, Yeon Hee
    Fernandez, Manuel Gonzalez
    Rubovszky, Gabor
    Spring, Laura
    Im, Seock-Ah
    Hui, Rina
    Takano, Toshimi
    Andre, Fabrice
    Yasojima, Hiroyuki
    Ding, Yu
    Jia, Liyi
    Karantza, Vassiliki
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NATURE MEDICINE, 2025, 31 (02) : 442 - 448
  • [10] Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk
    Sarkar, Swarnavo
    Schechter, Clyde
    Kurian, Allison W.
    Caswell-Jin, Jennifer L.
    Jayasekera, Jinani
    Mandelblatt, Jeanne S.
    NPJ BREAST CANCER, 2025, 11 (01)
12345